{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+and+Control&page=2", "query": { "condition": "Prevention and Control", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+and+Control&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:45:09.366Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00130026", "title": "Caffeine in the Prevention of Post-operative Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Postoperative Nausea and Vomiting" ], "interventions": [ { "name": "Caffeine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2005-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00130026" }, { "nct_id": "NCT04540185", "title": "A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19", "SARS (Severe Acute Respiratory Syndrome)", "SARS-CoV Infection", "SARS-CoV-2" ], "interventions": [ { "name": "Biological: oral polio vaccine", "type": "BIOLOGICAL" }, { "name": "Comparable Placebo", "type": "BIOLOGICAL" }, { "name": "NA-831", "type": "DRUG" }, { "name": "Comparable Placebo of drug", "type": "DRUG" }, { "name": "Combination of oral polio vaccine and NA-831", "type": "COMBINATION_PRODUCT" }, { "name": "Comparable Placebo of Oral Polio Vaccine and Placebo of drug", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3600, "start_date": "2020-11-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04540185" }, { "nct_id": "NCT05855655", "title": "Developing an Online Mindfulness-based Intervention to Reduce Minority Stress and HIV Risk Among Young Adult MSM - Aim 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hiv", "Minority Stress", "Mental Health Wellness 1" ], "interventions": [ { "name": "Mindfulness-Based Queer Resilience (MBQR)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "34 Years", "sex": "MALE", "summary": "18 Years to 34 Years · Male only" }, "enrollment_count": 68, "start_date": "2023-04-08", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05855655" }, { "nct_id": "NCT00152971", "title": "Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthroplasty, Replacement, Knee", "Thromboembolism" ], "interventions": [ { "name": "Dabigatran Dose 1 - day 2 to completion", "type": "DRUG" }, { "name": "Dabigatran Dose 1 - day 1", "type": "DRUG" }, { "name": "Dabigatran Dose 2 - day 2 to completion", "type": "DRUG" }, { "name": "Dabigatran Dose 2 - day 1", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2615, "start_date": "2004-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-05", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00152971" }, { "nct_id": "NCT00001034", "title": "The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections", "Gastrointestinal Diseases" ], "interventions": [ { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 850, "start_date": null, "completion_date": "1995-08", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 17, "location_summary": "San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001034" }, { "nct_id": "NCT04651634", "title": "MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Oral Mucositis" ], "interventions": [ { "name": "MIT-001 plus CCRT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MitoImmune Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-06-21", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Los Angeles, California • Wichita, Kansas + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04651634" }, { "nct_id": "NCT01393821", "title": "Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dermatologic Complications", "Malignant Neoplasm", "Pain" ], "interventions": [ { "name": "menadione topical lotion", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2012-01-23", "completion_date": "2018-07-14", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393821" }, { "nct_id": "NCT00452816", "title": "Marketing Workplace Chronic Disease Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Health Behavior", "Chronic Disease" ], "interventions": [ { "name": "Workplace Solutions Consulting approach", "type": "BEHAVIORAL" }, { "name": "Delayed intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 48, "start_date": "2007-04", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2009-11-20", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452816" }, { "nct_id": "NCT04505722", "title": "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol" ], "interventions": [ { "name": "Ad26.COV2.S", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44325, "start_date": "2020-09-07", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 117, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505722" }, { "nct_id": "NCT00054795", "title": "Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Metastases, Neoplasm" ], "interventions": [ { "name": "Motexafin Gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2007-05-08", "last_synced_at": "2026-05-22T09:45:09.366Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054795" } ] }